[[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methyl] (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 金鸡纳生物碱
• 英文名称: [[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methyl] (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
• 化学式: C₂₆H₃₄N₂O₈
• 分子量: 502.6
• InChiKey: ZWOAGWAAEYUBGX-YYXFHDJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  153
• 氢给体数：
  5
• 氢受体数：
  10

文献信息

• PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
  申请人：Acesion Pharma ApS

  公开号：EP2861254A2

  公开（公告）日：2015-04-22
• Pharmaceutical Compositions for Combination Therapy
  申请人：Acesion Pharma

  公开号：US20150164871A1

  公开（公告）日：2015-06-18

  This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective amount of a sodium channel inhibitor, in a combination with a small-conductance calcium-activated potassium (SK) channel inhibitor, for the treatment of cardiac arrhythmias.
• [EN] PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY<br/>[FR] COMPOSITIONS PHARMACEUTIQUES POUR POLYTHÉRAPIE
  申请人：ACESION PHARMA

  公开号：WO2013185764A2

  公开（公告）日：2013-12-19

  This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective amount of a sodium channel inhibitor, in a combination with a small-conductance calcium-activated potassium (SK) channel inhibitor, for the treatment of cardiac arrhythmias.